FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

被引：0
|
作者：
Alberto Zaniboni
Enrico Aitini
Sandro Barni
Daris Ferrari
Stefano Cascinu
Vincenzo Catalano
Giuseppe Valmadre
Domenica Ferrara
Enzo Veltri
Claudio Codignola
Roberto Labianca
机构：
[1] Fondazione Poliambulanza,Medical Oncology Unit
[2] C. Poma Hospital,Medical Oncology Unit
[3] Treviglio-Caravaggio Hospital,Medical Oncology Unit
[4] S. Paolo Hospital,Medical Oncology Unit
[5] Università Politecnica delle Marche,Medical Oncology Unit
[6] Ospedali Riuniti di Ancona,Medical Oncology Unit
[7] Ospedali Riuniti Marche Nord,Medical Oncology DH
[8] Presidio San Salvatore,Medical Oncology Unit
[9] Ospedale di Sondalo,Medical Oncology Unit
[10] Ospedale San Carlo,Department of Surgery
[11] Ospedale Don Luigi di Liegro,Medical Oncology Unit
[12] Fondazione Poliambulanza,undefined
[13] Ospedali Riuniti,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Pancreatic cancer; FOLFIRI; Chemotherapy; Second-line; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1641 / 1645
页数：4
相关论文
共 50 条
  • [21] Second-line treatment with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: Results of a multicenter phase II trial
    Boeck, Stefan
    Weigang-Koehler, Karin
    Fuchs, Martin
    Kettner, Erika
    Quietzsch, Detlev
    Trojan, Joerg
    Stoetzer, Oliver
    Mueller, Eva
    Depenbrock, Henrik
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2006, 17 : 322 - 322
  • [22] Second-line chemotherapy for advanced biliary tract cancer: Results of a multicenter survey
    Vasile, E.
    Di Girolamo, S.
    Cereda, S.
    Lonardi, S.
    Leone, F.
    Russano, M.
    Silvestris, N.
    Vivaldi, C.
    Fornaro, L.
    Brandi, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S614 - S614
  • [23] FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan
    Kobayashi, Noritoshi
    Omae, Katsuhiro
    Horita, Yosuke
    Ueno, Hideki
    Mizuno, Nobumasa
    Uesugi, Kazuhiro
    Sudo, Kentaro
    Ozaka, Masato
    Hayashi, Hideyuki
    Okano, Naohiro
    Kamei, Keiko
    Yamaguchi, Atsushi
    Kobayashi, Satoshi
    Suzuki, Shuhei
    Ishihara, Shin
    Uchiyama, Takashi
    Todaka, Akiko
    Fukutomi, Akira
    PANCREATOLOGY, 2020, 20 (07) : 1519 - 1525
  • [24] Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
    Brell, Joanna M.
    Matin, Khalid
    Evans, Terry
    Volkin, Robert L.
    Kiefer, Gauri J.
    Schlesselman, James J.
    Dranko, Shelley
    Rath, Linda
    Schmotzer, Amy
    Lenzner, Diana
    Ramanathan, Ramesh K.
    ONCOLOGY, 2009, 76 (04) : 270 - 274
  • [25] Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer
    Shi, Sheng-bin
    Wang, Meng
    Niu, Zuo-xing
    Tang, Xiao-yong
    Liu, Quan-yun
    PANCREATOLOGY, 2012, 12 (06) : 475 - 479
  • [26] A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study)
    Kodera, Yasuhiro
    Ito, Seiji
    Mochizuki, Yoshinari
    Fujitake, Shinichi
    Koshikawa, Katsumi
    Kanyama, Yasuaki
    Matsui, Takanori
    Kojima, Hiroshi
    Takase, Tsunenobu
    Ohashi, Norifumi
    Fujiwara, Michitaka
    Sakamoto, Junichi
    Nakao, Akimasa
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2667 - 2671
  • [27] Second-line chemotherapy in advanced bladder cancer
    Pavone-Macaluso, M
    Sternberg, C
    UROLOGIA INTERNATIONALIS, 2000, 64 (02) : 61 - 69
  • [28] Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
    Gransmark, Emma
    Bylin, Nellie Bagenholm
    Blomstrand, Hakon
    Fredrikson, Mats
    Avall-Lundqvist, Elisabeth
    Elander, Nils O.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [29] SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Cohn, Allen
    Dakhil, Shaker
    Saleh, Mansoor
    Piperdi, Bilal
    Cline-Burkhardt, Mika
    Tian, Ying
    Go, William Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (02) : 72 - 80
  • [30] A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
    C Yoo
    J Y Hwang
    J-E Kim
    T W Kim
    J S Lee
    D H Park
    S S Lee
    D W Seo
    S K Lee
    M-H Kim
    D J Han
    S C Kim
    J-L Lee
    British Journal of Cancer, 2009, 101 : 1658 - 1663
12345